Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
9.05
-0.03 (-0.33%)
Nov 21, 2024, 2:44 PM EST - Market open
Cogent Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
164
Market Cap
999.68M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Owens & Minor | 10.66B |
Brookdale Senior Living | 2.95B |
Phibro Animal Health | 1.05B |
Collegium Pharmaceutical | 599.25M |
HealthStream | 287.99M |
Weave Communications | 195.84M |
Avadel Pharmaceuticals | 138.16M |
Zymeworks | 62.20M |
COGT News
- 5 months ago - Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) - GlobeNewsWire
- 6 months ago - Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer - GlobeNewsWire
- 6 months ago - Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting - GlobeNewsWire
- 7 months ago - Cogent Biosciences Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 8 months ago - Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor - GlobeNewsWire
- 9 months ago - Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 9 months ago - Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis - GlobeNewsWire
- 10 months ago - Cogent Biosciences Announces Oversubscribed $225 Million Private Placement - GlobeNewsWire